These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12182865)

  • 1. Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor.
    Gallant M; Carrière MC; Chateauneuf A; Denis D; Gareau Y; Godbout C; Greig G; Juteau H; Lachance N; Lacombe P; Lamontagne S; Metters KM; Rochette C; Ruel R; Slipetz D; Sawyer N; Tremblay N; Labelle M
    Bioorg Med Chem Lett; 2002 Sep; 12(18):2583-6. PubMed ID: 12182865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor.
    Juteau H; Gareau Y; Labelle M; Sturino CF; Sawyer N; Tremblay N; Lamontagne S; Carrière MC; Denis D; Metters KM
    Bioorg Med Chem; 2001 Aug; 9(8):1977-84. PubMed ID: 11504634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor.
    Gallant M; Belley M; Carrière MC; Chateauneuf A; Denis D; Lachance N; Lamontagne S; Metters KM; Sawyer N; Slipetz D; Truchon JF; Labelle M
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3813-6. PubMed ID: 14552786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor.
    Ruel R; Lacombe P; Abramovitz M; Godbout C; Lamontagne S; Rochette C; Sawyer N; Stocco R; Tremblay NM; Metters KM; Labelle M
    Bioorg Med Chem Lett; 1999 Sep; 9(18):2699-704. PubMed ID: 10509919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists.
    Asada M; Obitsu T; Kinoshita A; Nakai Y; Nagase T; Sugimoto I; Tanaka M; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2639-43. PubMed ID: 20346663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.
    Burch JD; Belley M; Fortin R; Deschênes D; Girard M; Colucci J; Farand J; Therien AG; Mathieu MC; Denis D; Vigneault E; Lévesque JF; Gagné S; Wrona M; Xu D; Clark P; Rowland S; Han Y
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2048-54. PubMed ID: 18291643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3,4-Disubstituted indole acylsulfonamides: a novel series of potent and selective human EP3 receptor antagonists.
    Zhou N; Zeller W; Krohn M; Anderson H; Zhang J; Onua E; Kiselyov AS; Ramirez J; Halldorsdottir G; Andrésson T; Gurney ME; Singh J
    Bioorg Med Chem Lett; 2009 Jan; 19(1):123-6. PubMed ID: 19022669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.
    Walch L; de Montpreville V; Brink C; Norel X
    Br J Pharmacol; 2001 Dec; 134(8):1671-8. PubMed ID: 11739243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists.
    Hategan G; Polozov AM; Zeller W; Cao H; Mishra RK; Kiselyov AS; Ramirez J; Halldorsdottir G; Andrésson T; Gurney ME; Singh J
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6797-800. PubMed ID: 19836233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).
    Flesch D; Merk D; Lamers C; Schubert-Zsilavecz M
    Expert Opin Ther Pat; 2013 Feb; 23(2):233-67. PubMed ID: 23289354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry.
    Juteau H; Gareau Y; Labelle M; Lamontagne S; Tremblay N; Carrière MC; Sawyer N; Denis D; Metters KM
    Bioorg Med Chem Lett; 2001 Mar; 11(5):747-9. PubMed ID: 11266183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin E2 suppression of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by interacting with prostanoid receptors of the EP3-subtype.
    Spicuzza L; Giembycz MA; Barnes PJ; Belvisi MG
    Br J Pharmacol; 1998 Mar; 123(6):1246-52. PubMed ID: 9559911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization and identification of EP3 prostanoid receptor binding sites in hamster uterus homogenates.
    Sharif NA; Xu SX
    J Pharm Pharmacol; 2004 Feb; 56(2):197-203. PubMed ID: 15005878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of a new class of selective EP3 receptor agonist, 13,14-didehydro-16-phenoxy analogues of prostaglandin E1.
    Shimazaki Y; Kameo K; Tanami T; Tanaka H; Ono N; Kiuchi Y; Okamoto S; Sato F; Ichikawa A
    Bioorg Med Chem; 2000 Feb; 8(2):353-62. PubMed ID: 10722158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification in human airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE2 inhibits the release of GM-CSF.
    Clarke DL; Belvisi MG; Catley MC; Yacoub MH; Newton R; Giembycz MA
    Br J Pharmacol; 2004 Apr; 141(7):1141-50. PubMed ID: 15023863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro characterization of prostanoid EP-receptors in the non-pregnant human myometrium.
    Senior J; Marshall K; Sangha R; Baxter GS; Clayton JK
    Br J Pharmacol; 1991 Mar; 102(3):747-53. PubMed ID: 1285399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E₂ inhibits human lung fibroblast chemotaxis through disparate actions on different E-prostanoid receptors.
    Li YJ; Wang XQ; Sato T; Kanaji N; Nakanishi M; Kim M; Michalski J; Nelson AJ; Sun JH; Farid M; Basma H; Patil A; Toews ML; Liu X; Rennard SI
    Am J Respir Cell Mol Biol; 2011 Jan; 44(1):99-107. PubMed ID: 20203295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere.
    Downey JD; Saleh SA; Bridges TM; Morrison RD; Daniels JS; Lindsley CW; Breyer RM
    Bioorg Med Chem Lett; 2013 Jan; 23(1):37-41. PubMed ID: 23218714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.
    Orie NN; Clapp LH
    Eur J Pharmacol; 2011 Mar; 654(3):258-65. PubMed ID: 21185823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds.
    Woodward DF; Krauss AH; Chen J; Gil DW; Kedzie KM; Protzman CE; Shi L; Chen R; Krauss HA; Bogardus A; Dinh HT; Wheeler LA; Andrews SW; Burk RM; Gac T; Roof MB; Garst ME; Kaplan LJ; Sachs G; Pierce KL; Regan JW; Ross RA; Chan MF
    Br J Pharmacol; 2000 Aug; 130(8):1933-43. PubMed ID: 10952685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.